GeoVax Labs, Inc. (Nasdaq: GOVX) reported financial results for the second quarter of 2026 and provided a business update, highlighting continued progress toward the planned initiation of a pivotal immunobridging study for its GEO-MVA vaccine candidate. The study, expected to begin in the fourth quarter of 2026, will be conducted under an expedited regulatory pathway established through formal Scientific Advice discussions with the European Medicines Agency (EMA).
During the quarter, GeoVax advanced clinical operations planning, start-up activities, and manufacturing preparedness. The company utilized previously manufactured and released cGMP clinical trial material and advanced its AGE1 continuous cell-line manufacturing platform for future commercial-scale MVA vaccine production. GeoVax also engaged with government, public health, and biodefense stakeholders regarding long-term orthopoxvirus preparedness and vaccine supply requirements.
"During the second quarter, we continued executing against what we believe is one of our most important value-creating milestones, as we prepare to initiate the pivotal GEO-MVA immunobridging study," said David A. Dodd, Chairman and CEO of GeoVax. "Our priorities remain clear: completing the activities necessary to initiate the study, maintaining disciplined capital allocation, and positioning GEO-MVA to address the growing global need for diversified MVA vaccine supply supporting public health preparedness and biodefense."
In its immuno-oncology program, GeoVax continues advancing Gedeptin, a gene-directed enzyme prodrug therapy (GDEPT), toward combination strategies designed to enhance immune checkpoint inhibitor activity. The company believes Gedeptin's localized tumor-targeting mechanism may complement PD-1-based therapies such as Merck's Keytruda by improving responsiveness in immunologically resistant tumors. GeoVax holds an exclusive intellectual property license from Emory University covering Gedeptin in combination with immune checkpoint inhibitors.
Financially, GeoVax reported a net loss of $4.4 million for the second quarter of 2026, compared to $5.4 million in the same period of 2025. The decrease was primarily due to lower research and development expenses, which fell to $3.1 million from $4.7 million, reflecting reduced costs from discontinued activities related to the BARDA contract and GEO-CM04S1 clinical activities. General and administrative expenses also decreased to $1.3 million from $1.5 million. The company reported no revenue from government contracts in the 2026 period, compared to $0.9 million in the prior year, following the termination of the BARDA contract in April 2025. Cash and cash equivalents stood at $3.1 million as of June 30, 2026, unchanged from year-end 2025.
GeoVax's strategic reprioritization, announced in May 2026, focuses resources on GEO-MVA and Gedeptin, reflecting clearer regulatory pathways and stronger demand visibility. The decision to discontinue active development of GEO-CM04S1 was not due to safety or efficacy concerns but rather the evolution of the global COVID-19 vaccine market.
GEO-MVA is GeoVax's Modified Vaccinia Ankara (MVA)-based vaccine candidate for protection against mpox and smallpox. The program is advancing under an expedited regulatory pathway designed to support potential regulatory approval through a single pivotal immunobridging study demonstrating non-inferiority to an approved MVA vaccine. More information is available at www.geovax.com.
